Form 10-Q Arcutis Biotherapeutics, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
Mizuho Reiterates Outperform Rating on Arcutis Biotherapeutics Inc. (ARQT)
August 16, 2024 2:59 PM EDTMizuho analyst Uy Ear reiterated an Outperform rating and $19.00 price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT)
The analyst comments "For the week ending 08/09/2024, the Zoryve franchise grew 10.5% (vs +4.2% in the prior week) for TRxs and 6.3% (vs +12.4% in the prior week) for... More
